UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2016
Pages: 50
US$ 499.00
UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
UCB SA Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between UCB SA and its competitors. This provides our Clients with a clear understanding of UCB SA position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about UCB SA that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for UCB SA. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The UCB SA financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes UCB SA competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of UCB SA business.

About UCB SA

UCB S.A. operates as a biopharmaceutical company that focuses on three therapeutic areas – the central nervous system (CNS), inflammation and immunology (including allergy), and oncology in Belgium. The company operates in approximately 40 countries worldwide. Its major global markets include the U.S., Europe and Japan.

UCB’s major pharmaceutical products include:

Keppra (levetiracetam)

Keppra is an antiepileptic, which significantly reduces the frequency of epileptic attacks. Keppra is indicated as an add-on therapy for partial onset seizures with or without secondary generalized seizures for epilepsy patients aged approximately 16 years. Keppra was filed in the U.S. in December 2004 and in Europe in March 2005, as an application for a new intravenous formulation. In the fourth quarter of 2004, the company also filed a paediatric indication of Keppra (for patients aged 4-16) in the U.S. and Europe.

Xyzal (levocetirizine) and Zyrtec (cetirizine)

Xyzal (levocetirizine) and Zyrtec (cetirizine) are antiallergics prescribed for seasonal rhinitis, perennial rhinitis and chronic idiopathic urticaria. A Phase III EPAAC study (Early Prevention of Asthma in Atopic Children) is underway to test the hypothesis that Xyzal can delay the onset of asthma in atopic children.


Xyrem is the FDA-approved medication for the treatment of cataplexy (sudden loss of control over voluntary muscle movement) associated with narcolepsy.

Nootropil (piracetam)

Nootropil is a cerebral function regulator and first in the class of ‘nootropic’ agents.


Atarax (hydroxyzine) is a non-benzodiazepinic tranquilliser.


Lortab (hydrocodone-paracetamol), an analgesic, which reduces sensitivity to most types of pain.


Tussionex is the 12-hour hydrocodone-based prescription syrup for coughs and colds, enabling UCB to offer a range of respiratory therapies.

Metadate CD / Equasym XL

Unique extended-release formulation of the most commonly used treatment of Attention Deficit and Hyper activity Disorder (ADHD). Marketed in the U.S. as Metadate CD, this once-daily methylphenidate has an extended release formulation, enabling children to maintain their attention throughout the school day more effectively, without affecting their appetite or sleep patterns in the evening. The company intends to launch it in Europe in 2005 under the brand name Equasym XL. In February 2005, Equasym XL was approved for marketing and launched in the UK.


Dipentum is a treatment for ulcerative colitis.


Somatostatin-UCB is for the treatment of patients suffering from haemorrhaging of the oesophagus and post-operative gastro-intestinal fistulas.

Brivaracetam (UCB34714)

Brivaracetam is a broad-spectrum product in development. Phase II clinical trials including patients with photosensitive epilepsy produced preliminary results suggesting the compound is more potent than Keppra and provides suppression of light-induced electro encephalogram (EEG) abnormalities. Brivaracetam has also demonstrated some preclinical activity in the treatment of neuropathic pain and essential tremor.

Seletracetam (UCB4412)

Seletracetam is a SV2A ligand in development. Seletracetam reduces high-voltage-activated calcium currents, providing UCB with another avenue for tackling the heterogeneous nature of epilepsy. A Phase I clinical trial has indicated that this compound is well tolerated and preclinically even more potent than Keppra.

Attention deficit/hyperactivity disorder (ADHD)


CDP323 has potential in tackling the inflammation associated with several major diseases. Preclinical data demonstrates activity in multiple sclerosis, rheumatoid arthritis and asthma. There is additional potential for this product in psoriasis. CDP323 is a smallmolecule inhibitor of alpha-4 integrins. Its mechanism of action is to stop white blood cells migrating to and exacerbating areas of inflammation. As a small molecule, it can be taken orally. CDP323 completed a Phase I multipledose study.


Efletirizine is a novel antihistamine with a promising onset of action and safety profile.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. UCB SA Direct Competitors
5.2. Comparison of UCB SA and Direct Competitors Financial Ratios
5.3. Comparison of UCB SA and Direct Competitors Stock Charts
5.4. UCB SA Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. UCB SA Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





UCB SA Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
UCB SA Key Executives
Key Executives Biographies1
Key Executives Compensations1
UCB SA Major Shareholders
UCB SA History
UCB SA Products
Revenues by Segment
Revenues by Region
UCB SA Offices and Representations
UCB SA SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
UCB SA Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
UCB SA Capital Market Snapshot
UCB SA Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
UCB SA Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
UCB SA Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


UCB SA Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
UCB SA 1-year Stock Charts
UCB SA 5-year Stock Charts
UCB SA vs. Main Indexes 1-year Stock Chart
UCB SA vs. Direct Competitors 1-year Stock Charts
UCB SA Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

UCB business profile (company report) US$ 99.00 Aug, 2011 · 30 pages
UCB Group – Product Pipeline Review – Q4 2010 US$ 500.00 Dec, 2010 · 54 pages
UCB Group (UCB): Company Profile and SWOT Analysis US$ 125.00 Jul, 2012 · 37 pages

Ask Your Question

UCB SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: